EpicentRx, Inc., a La Jolla, Calif.-based clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, raised $35m in Series D funding.
The backer was an undisclosed investor from Europe.
The company intends to use the funds, which will be split into three tranches, to progress the late-stage clinical development of its lead anticancer agent, RRx-001, and proprietary transgene-enhanced oncolytic adenoviral platform technology.
Led by Corey A. Carter, M.D., President & CEO, and Tony Reid, M.D., Ph.D., Chief Scientific Officer and Professor of Medicine at the University of California San Diego Moores Cancer Center, EpicentRx is a patient-driven oncology company developing new mechanisms of immunotherapy that work across diverse patient populations and tumor types with minimal toxicity, enabling the best-possible quality of life during treatment.
EpicentRx is advancing RRx-001, a small molecule immunotherapy targeting the CD47 – SIRPα axis. The drug is currently being evaluated in combination with platinum doublet chemotherapy in the Phase 3 REPLATINUM trial for the treatment of third-line and beyond small cell lung cancer.
It is also developing a diverse array of oncolytic adenoviruses that are genetically engineered to replicate selectively in cancer cells.
The Series D brings the total capital raised by EpicentRx to approximately $77m.